Merck doubles down on Galapagos discovery deal

Merck is doubling down on its research collaboration with Galapagos. Building on a deal struck at the beginning of the year, Merck has boosted its commitment on milestones for new atherosclerosis therapies to more than €400 million. In the pact, Galapagos will be responsible for the discovery and pre-clinical development of new small molecule candidate drugs based on novel Galapagos targets. "Merck's extended collaboration with Galapagos underscores our ongoing commitment to identifying novel therapeutic targets for fighting cardiovascular and metabolic diseases," said Merck's Catherine Strader. Galapagos release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.